NIH Director Research Articles

NIEHS Employees Honored by NIH Director and Public Health Service

NIEHS Employees Honored by NIH Director and Public Health Service

NIEHS Employees Honored by NIH Director and Public Health Service

NIEHS Employees Honored by NIH Director and Public Health Service

Basic science and the NIH.

The following is an edited version of the Keynote Speech delivered at the Annual Meeting of the American Society for Cell Biology by Harold Varmus, Director of the National Institutes of Health. The address, entitled Basic Science and the NIH, was given at the opening of the meeting in New Orleans on December 11, 1993. It was Varmus' first public policy talk as NIH Director.

New NIH director faces filling top posts, focus on intramural research

New NIH director faces filling top posts, focus on intramural research

New NIH Director

New NIH Director

Nobel Laureate May Be Next NIH Director

Journal Article Nobel Laureate May Be Next NIH Director Get access JNCI: Journal of the National Cancer Institute, Volume 85, Issue 15, 4 August 1993, Page 1189, https://doi.org/10.1093/jnci/85.15.1189 Published: 04 August 1993

NIH director. Varmus opposition raises anxieties.

NIH director. Varmus opposition raises anxieties.

NIH Peer Reviewers To Watch For High-Risk, High-Payoff Proposals

When the National Institutes of Health's study sections (peer review groups) meet this month to consider the latest sets of applications for NIH grants, they will be given a new task. In addition to ranking each proposal based on its scientific merit, the reviewers will be asked to pay particular attention to identifying studies that are both high risk and have the potential for a high return. Such proposals won't get a higher ranking than they otherwise would have, says Jerome G. Green, director of NIH's division of research grants. But they will be flagged as something unique. Then the NIH advisory councils—the committees that make the final decisions on which applications get funded—will have the option of giving the innovative applications special treatment. Green described the new targeting mechanism to a special session of the advisory council of the National Institute of General Medical Sciences (NIGMS). The group devoted a full afternoon last month ...

Recommendations of the RAC to the NIH Director, January 14, 1993

Human Gene TherapyVol. 4, No. 2 DocumentsRecommendations of the RAC to the NIH Director, January 14, 1993Published Online:16 Jul 2008https://doi.org/10.1089/hum.1993.4.2-203AboutSectionsPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail "Recommendations of the RAC to the NIH Director, January 14, 1993." , 4(2), p. 203FiguresReferencesRelatedDetailsCited byCommentary: Reconstruing Genetic Research as Research23 June 2016 | The Journal of Law, Medicine & Ethics, Vol. 26, No. 1 Volume 4Issue 2Apr 1993 InformationCopyright 1993, Mary Ann Liebert, Inc.To cite this article:Recommendations of the RAC to the NIH Director, January 14, 1993.Human Gene Therapy.Apr 1993.203-203.http://doi.org/10.1089/hum.1993.4.2-203Published in Volume: 4 Issue 2: July 16, 2008PDF download

Controversial AIDS vaccine trial backed

An advisory panel of AIDS experts convened by the National Institutes of Health recommended last week that the Army proceed with a controversial large clinical trial of a vaccine designed to boost the immune systems of people infected with the AIDS virus. But the trial must test all available vaccine candidates, the panel voted—not just the particular product specified by Congress in the Defense Department's 1993 appropriation bill. In a move arousing widespread criticism, Congress voted in October to give the Army $20 million to expand its testing of gpl60, a genetically engineered vaccine manufactured by MicroGeneSys Inc., a biotechnology research firm based in Meriden, Conn. The biomedical research community reacted angrily, charging Congress with bypassing the usual scientific review process by earmarking funds in response to the company's lobbying. I have concerns and reservations about the process by which gpl60 was selected by Congress for the proposed efficacy trial, said NIH director Bernadine ...

Basic research: the lifeline of medicine

The FASEB JournalVolume 6, Issue 13 p. 3143-3145 Highlights Basic research: the lifeline of medicine Arthur Kornberg, Arthur Kornberg Department of Biochemistry, Stanford University School of Medicine, Beckman Center, Stanford, California, 94305-5307 USAEditor's note: This address was given by Dr. Kornberg at a national symposium on “Today's Opportunities, Tomorrow's Health: The Future of Biomedical Research in America” held in San Antonio, Texas, February 2–4, 1992, to mark the 50th anniversary of the Southwest Foundation for Biomedical Research, and co-sponsored by the U.S. Department of Health and Human Services and the National Institutes of Health. Dr. Kornberg's talk followed one by NIH Director Bernadine Healy in which she presented NIH's targeting of specific health (disease) goals. Dr. Kornberg's address is reproduced from the symposium report by permission of the copyright holder. Elements of the address are reprinted with permission from Clinical Chemistry, (1991), Vol 37, No 11, pages 1895–1899, entitled: “Understanding Life as Chemistry.” Copyright American Association for Clinical Chemistry, Inc.Search for more papers by this author Arthur Kornberg, Arthur Kornberg Department of Biochemistry, Stanford University School of Medicine, Beckman Center, Stanford, California, 94305-5307 USAEditor's note: This address was given by Dr. Kornberg at a national symposium on “Today's Opportunities, Tomorrow's Health: The Future of Biomedical Research in America” held in San Antonio, Texas, February 2–4, 1992, to mark the 50th anniversary of the Southwest Foundation for Biomedical Research, and co-sponsored by the U.S. Department of Health and Human Services and the National Institutes of Health. Dr. Kornberg's talk followed one by NIH Director Bernadine Healy in which she presented NIH's targeting of specific health (disease) goals. Dr. Kornberg's address is reproduced from the symposium report by permission of the copyright holder. Elements of the address are reprinted with permission from Clinical Chemistry, (1991), Vol 37, No 11, pages 1895–1899, entitled: “Understanding Life as Chemistry.” Copyright American Association for Clinical Chemistry, Inc.Search for more papers by this author First published: 01 October 1992 https://doi.org/10.1096/fasebj.6.13.1397835Citations: 4 AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article.Citing Literature Volume6, Issue13October 1992Pages 3143-3145 RelatedInformation

Scientific Community Grapples with Proposed Strategic Plan for NIH

Some 250 eminent scientists gathered near Washington, D.C., this past month to mull over the National Institutes of Health's proposed strategic plan. After two days of deliberations, there was still no finished plan in the sense of a document that spells out specific goals, strategies, timetables, and procedures. But the task force of working scientists and research administrators succeeded in outlining what they consider some of the most important lines of research for the coming decade. And the skepticism with which many had initially greeted NIH director Bernadine P. Healy's effort to set priorities for the biomedical research agency had diminished. NIH's 1992 budget of about $9 billion ranks it as the largest single source of funding for health-related research in the world. It is a pillar of chemical research, supporting about 30% of all federally funded chemistry in universities. Healy began her drive for long-range planning at NIH almost as soon as she took ...

From the National Institute on Deafness and Other Communication Disorders.

Otolaryngology–Head and Neck SurgeryVolume 106, Issue 3 p. 311-314 From the NIPCD From the National Institute on Deafness and other Communication Disorders James B. Snow Jr. MD, NIDCD, NIH, Corresponding Author James B. Snow Jr. MD, NIDCD, NIH Director n/[email protected] National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MarylandReprint requests: James B. Snow, Jr., MD, Director, NIDCD, NIH, Building 31, Room 3C-02, Bethesda, MD 20892.Search for more papers by this author James B. Snow Jr. MD, NIDCD, NIH, Corresponding Author James B. Snow Jr. MD, NIDCD, NIH Director n/[email protected] National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MarylandReprint requests: James B. Snow, Jr., MD, Director, NIDCD, NIH, Building 31, Room 3C-02, Bethesda, MD 20892.Search for more papers by this author First published: 01 March 1992 https://doi.org/10.1177/019459989210600322AboutPDF ToolsExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Volume106, Issue3March 1992Pages 311-314 RelatedInformation

NIH files second human gene patent application

The National Institutes of Health last week filed its second patent application covering human brain gene sequences identified by one of its researchers, despite the controversy raised by its first patent application last summer. [will] continue filing patents while an important debate unfurls as to what is the best way to deal with intellectual property issues surrounding partial or full gene sequences, NIH director Bernadine Healy told a press conference. If we had chosen not to file, it would have closed doors on any future options, should these materials be found to have intellectual property value. The application covers 2375 genes identified and partially sequenced by a novel strategy developed by J. Craig Venter and coworkers at the National Institute of Neurological Disorders & Stroke. It is an extension of NIH's previous application, still pending, which covered about 350 genes. NIH filed the extension simultaneously with publication of Venter's ...

New NIH Director Holds Town Meeting

New NIH Director Holds Town Meeting

ScienceScope

ScienceScope

Of July 18, 1991: Announcement of NIH Director's Approval of Human Gene Transfer Protocols

Of July 18, 1991: Announcement of NIH Director's Approval of Human Gene Transfer Protocols

NIH Director Faces Congressional Scrutiny

NIH Director Faces Congressional Scrutiny

NIH STRATEGIC PLAN: Director Healy sets ambitious course

National Institutes of Health director Bernadine P. Healy is developing a long-range strategic plan that would sharply increase the number of research grants NIH supports from the current level of roughly 21,000 per year to 30,000 or more by the mid-1990s. Healy outlined this and other aspects of an ambitious plan on July 18. She spoke at her first meeting with the NIH Director's Advisory Committee—a panel on which she used to serve—since taking the helm at NIH in April. NIH, with an $8 billion budget for fiscal 1991, is the largest single source of biomedical research funding in the world. It provides about one third of all federal money for academic chemistry research. NIH should go from 20,000 to 40,000 grants to accommodate all the research opportunities, Healy told the committee. However, she conceded, a proposal to double the size of the NIH grant portfolio likely would never make it past budget watchers at ...

Late Breaking News: Healy Sworn In as NIH Director

Late Breaking News: Healy Sworn In as NIH Director